3-(1,3-二恶烷-2-基)丙酸 | 774605-67-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 中文名称: 3-(1,3-二恶烷-2-基)丙酸
• 英文名称: 3-(1,3-dioxan-2-yl)propanoic acid
• CAS: 774605-67-3
• 化学式: C₇H₁₂O₄
• mdl: MFCD07700144
• 分子量: 160.17
• InChiKey: BWKVHROEJJTCAU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  3-(1,3-二恶烷-2-基)丙酸 在 sodium hydroxide 、 sodium methylate 、 N,N'-羰基二咪唑 、 magnesium chloride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 3-(2,6-Dichloro-phenyl)-5-(2-[1,3]dioxan-2-yl-ethyl)-isoxazole-4-carboxylic acid
  参考文献：
  名称：

  Novel isoxazole carboxamides as growth hormone secretagogue receptor (GHS-R) antagonists

  摘要：

  Novel isoxazole carboxamides have been identified as growth hormone secretagogue receptor (GHS-R) antagonists. Substituent modification off the 5-position of the isoxazole ring led to analogues with potent binding affinity and functional antagonism of GHS-R. A potent analogue (32) with high aqueous solubility and good GPCR selectivity was also identified as a potential pharmacological tool for in vivo studies. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.06.060
• 作为产物：
  描述：

  2-(2-溴乙基)-1,3-二氧杂环己烷 、 二氧化碳 在 锰 、 氯化镍二甲氧基乙烷 、 2,9-diethyl-1,10-phenanthroline 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 12.0h， 以55%的产率得到3-(1,3-二恶烷-2-基)丙酸
  参考文献：
  名称：

  Ni-Catalyzed Carboxylation of Unactivated Primary Alkyl Bromides and Sulfonates with CO₂

  摘要：

  A Ni-catalyzed carboxylation of unactivated primary alkyl bromides and sulfonates with CO2 at atmospheric pressure is described. The method is characterized by its mild conditions and remarkably wide scope without the need for air- or moisture-sensitive reagents, which make it a user-friendly and operationally simple protocol en route to carboxylic acids.

  DOI：

  10.1021/ja5064586

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS<br/>[FR] COMPOSÉS ET COMPOSITIONS POUVANT ÊTRE UTILISÉS EN TANT QU'INHIBITEURS DE LA KINASE C-KIT
  申请人：IRM LLC

  公开号：WO2013033116A1

  公开（公告）日：2013-03-07

  The invention provides compounds of formulae (I) and (II) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

  该发明提供了式(I)和(II)的化合物以及其药物组合物，这些化合物可用作蛋白激酶抑制剂，以及使用这些化合物治疗、改善或预防与异常或失调激酶活性相关的疾病的方法。在某些实施例中，该发明提供了使用这些化合物治疗、改善或预防涉及c-kit或c-kit和PDGFR（PDGFRα，PDGFRβ）激酶异常激活的疾病或紊乱的方法。
• [EN] FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS<br/>[FR] ANALOGUES À CYCLES CONDENSÉS D'AGENTS ANTI-FIBROTIQUES
  申请人：FIBROTECH THERAPEUTICS PTY LTD

  公开号：WO2011047432A1

  公开（公告）日：2011-04-28

  The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment disorders.

  本发明涉及可能用作抗纤维化剂的芳基羰基和杂芳基羰基蒽酰胺化合物。本发明还涉及它们的制备方法、含有这些化合物的药物组合物以及这些化合物在治疗疾病中的用途。
• COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS
  申请人：Liu Xiaodong

  公开号：US20150011508A1

  公开（公告）日：2015-01-08

  The invention provides compounds of formulae (I) and (II) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

  本发明提供了式（I）和式（II）的化合物及其制药组合物，它们可用作蛋白激酶抑制剂，以及使用这些化合物治疗、改善或预防与异常或失调激酶活性相关的病症的方法。在某些实施例中，本发明提供使用这些化合物治疗、改善或预防涉及c-kit或c-kit和PDGFR（PDGFRα，PDGFRβ）激酶异常活化的疾病或障碍的方法。
• Synthesis and structure–activity relationships of isoxazole carboxamides as growth hormone secretagogue receptor antagonists
  作者：Zhili Xin、Hongyu Zhao、Michael D. Serby、Bo Liu、Verlyn G. Schaefer、Douglas H. Falls、Wiweka Kaszubska、Christine A. Colins、Hing L. Sham、Gang Liu

  DOI：10.1016/j.bmcl.2004.11.075

  日期：2005.2

  A series of isoxazole carboxamide derivatives has been developed as potent ghrelin receptor antagonists. The synthesis and structure-activity relationship (SAR) are described. (C) 2004 Elsevier Ltd. All rights reserved.